Anavex Life Sciences Corp
AVXL12.130USD
-0.610-4.79%
종가 07/25, 16:00（ET）시세는 15분 지연됩니다
1.04B시가총액
손실P/E TTM
자세한 내용은 Anavex Life Sciences Corp 회사
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
회사 정보
종목 코드 AVXL
회사 이름Anavex Life Sciences Corp
상장일Apr 13, 2006
설립일2004
CEODr. Christopher U. Missling, Ph.D.
직원 수42
유형Ordinary Share
회계 연도 종료Apr 13
주소630 5Th Avenue
도시NEW YORK
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호10111
전화18446893939
웹사이트https://www.anavex.com
종목 코드 AVXL
상장일Apr 13, 2006
설립일2004
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, May 16
마지막 업데이트: Fri, May 16
주주
주주 유형
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
7.00%
The Vanguard Group, Inc.
5.72%
State Street Global Advisors (US)
3.77%
Geode Capital Management, L.L.C.
2.30%
Missling (Christopher U)
1.72%
Other
79.49%
주주
주주
비율
BlackRock Institutional Trust Company, N.A.
7.00%
The Vanguard Group, Inc.
5.72%
State Street Global Advisors (US)
3.77%
Geode Capital Management, L.L.C.
2.30%
Missling (Christopher U)
1.72%
Other
79.49%
주주 유형
주주
비율
Investment Advisor
22.93%
Investment Advisor/Hedge Fund
9.72%
Individual Investor
3.33%
Hedge Fund
2.49%
Research Firm
1.58%
Bank and Trust
0.78%
Pension Fund
0.24%
Insurance Company
0.03%
Other
58.91%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
353
35.09M
41.11%
+424.70K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
2023Q1
340
29.94M
37.61%
-3.19M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
BlackRock Institutional Trust Company, N.A.
5.98M
7%
+20.29K
+0.34%
Mar 31, 2025
The Vanguard Group, Inc.
4.88M
5.72%
+202.97K
+4.34%
Mar 31, 2025
State Street Global Advisors (US)
3.21M
3.77%
+802.33K
+33.26%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.96M
2.3%
+89.89K
+4.79%
Mar 31, 2025
Missling (Christopher U)
1.47M
1.72%
--
--
Apr 25, 2025
Two Sigma Investments, LP
1.37M
1.6%
+100.80K
+7.95%
Mar 31, 2025
Skarpelos (Athanasios)
1.31M
1.53%
--
--
Apr 25, 2025
Northwest Asset Management
1.00M
1.17%
+87.30K
+9.56%
Mar 31, 2025
Susquehanna International Group, LLP
787.10K
0.92%
-347.64K
-30.64%
Mar 31, 2025
Northern Trust Investments, Inc.
674.75K
0.79%
-26.63K
-3.80%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
이름
비율
Invesco Dorsey Wright Healthcare Momentum ETF
1.85%
iShares Neuroscience and Healthcare ETF
1.48%
ALPS Medical Breakthroughs ETF
0.54%
Invesco Dorsey Wright SmallCap Momentum ETF
0.28%
SPDR S&P Biotech ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Momentum Factor ETF
0.12%
iShares Micro-Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
더 보기
Invesco Dorsey Wright Healthcare Momentum ETF
비율1.85%
iShares Neuroscience and Healthcare ETF
비율1.48%
ALPS Medical Breakthroughs ETF
비율0.54%
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.28%
SPDR S&P Biotech ETF
비율0.22%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.14%
Vanguard US Momentum Factor ETF
비율0.12%
iShares Micro-Cap ETF
비율0.12%
ProShares Ultra Nasdaq Biotechnology
비율0.09%
iShares Biotechnology ETF
비율0.07%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
